$420,000 of EXACT SCIENCES lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"HR 842/S 339 support Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act. Support colorectal cancer screening standards Support patient access to cancer screening and diagnostics. Support HR 1780/S 642 Finn Sawyer Access to Cancer Testing Act Support S 1410 Find It Early Act Support HR 2921/S 2745 Federal Firefighter Cancer Detection and Prevention Act of 2025 Support HR 1610 FIRE Cancer Act Support HR 4752/S 2760 Reducing Hereditary Cancer Act Support HR 7714 Colorectal Cancer Early Detection Act Support S 1717 Ensuring Patient Access to Critical Breakthrough Products Act Support veteran access to guideline-recommended colorectal cancer screening."
You can find more data on corporate lobbying on Quiver Quantitative.
EXAS Insider Trading Activity
EXAS insiders have traded $EXAS stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- KATHERINE S ZANOTTI sold 12,000 shares for an estimated $780,000
- JACOB A ORVILLE (EVP, GM, Screening) sold 5,000 shares for an estimated $375,000
- JAMES HERRIOTT (SVP, General Counsel & Sec) has made 0 purchases and 3 sales selling 4,000 shares for an estimated $265,120.
- BRIAN BARANICK (EVP, GM, Precision Oncology) sold 2,858 shares for an estimated $200,288
- JAMES EDWARD DOYLE has made 0 purchases and 2 sales selling 3,485 shares for an estimated $182,399.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXAS Hedge Fund Activity
We have seen 291 institutional investors add shares of EXAS stock to their portfolio, and 257 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 8,241,935 shares (-30.6%) from their portfolio in Q3 2025, for an estimated $450,916,263
- WELLINGTON MANAGEMENT GROUP LLP removed 6,677,809 shares (-55.6%) from their portfolio in Q3 2025, for an estimated $365,342,930
- CITADEL ADVISORS LLC added 3,506,084 shares (+805.1%) to their portfolio in Q3 2025, for an estimated $191,817,855
- CANADA PENSION PLAN INVESTMENT BOARD added 2,500,056 shares (+2439.1%) to their portfolio in Q3 2025, for an estimated $136,778,063
- AMERIPRISE FINANCIAL INC added 2,270,039 shares (+102.1%) to their portfolio in Q3 2025, for an estimated $124,193,833
- ARK INVESTMENT MANAGEMENT LLC added 2,186,132 shares (+6072588.9%) to their portfolio in Q3 2025, for an estimated $119,603,281
- CAPITAL WORLD INVESTORS removed 2,059,161 shares (-11.3%) from their portfolio in Q3 2025, for an estimated $112,656,698
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXAS Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 11/11/2025
- TD Cowen issued a "Buy" rating on 11/04/2025
- Baird issued a "Outperform" rating on 11/04/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Craig-Hallum issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for EXAS, check out Quiver Quantitative's $EXAS forecast page.
EXAS Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 16 analysts offer price targets for $EXAS in the last 6 months, with a median target of $86.5.
Here are some recent targets:
- Anthony Petrone from Mizuho set a target price of $105.0 on 01/20/2026
- Vijay Kumar from Evercore ISI Group set a target price of $105.0 on 01/05/2026
- Kyle Mikson from Canaccord Genuity set a target price of $105.0 on 11/25/2025
- Brandon Couillard from Jefferies set a target price of $105.0 on 11/24/2025
- Brandon Couillard from Wells Fargo set a target price of $105.0 on 11/21/2025
- Luke Sergott from Barclays set a target price of $105.0 on 11/21/2025
- David Westenberg from Piper Sandler set a target price of $80.0 on 11/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
